PDCD1 and neoplasm: Another study in in vitro and xenograft mouse models demonstrated that the PD-1 inhibitory antibody dramatically improved the anti-tumor efficacy of the DLL3 bispecific antibody [105], suggesting the feasibility of DLL3 CAR-T combined with PD-1 inhibitors.